SCIENTECH(02291.HK)

Company Encyclopedia
View More
name
SCIENTECH
02291.HK
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., an investment holding company, engages in the manufacture and sale of interventional treatment series occluders for defective congenital heart disease. It operates through Occluder Business and Heart Valve Business segments. The company also research and develops heart valve medical devices. Its products include atrial septal defect, ventricular septal defect, patent ductus arteriosus, patent foramen ovale, left atrial appendage, aortic and peripheral, and aortic and mitral valve occluder products; atrial septal puncture and procedural accessories; interatrial shunt device; mechanical circulatory support products; and hypertensive device treatment products.
136.55 B
02291.HKMarket value -Rank by Market Cap -/-

Financial Score

31/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking5/26
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE14.91%A
    • Profit Margin52.03%A
    • Gross Margin86.24%A
  • Growth ScoreA
    • Revenue YoY35.11%A
    • Net Profit YoY33.21%B
    • Total Assets YoY8.00%B
    • Net Assets YoY6.86%B
  • Cash ScoreB
    • Cash Flow Margin192.18%C
    • OCF YoY35.11%A
  • Operating ScoreD
    • Turnover0.25D
  • Debt ScoreA
    • Gearing Ratio13.42%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Lepu Scientech Medical Technology Appoints New Joint Company Secretary and Process Agent

    Lepu Scientech Medical Technology Shanghai Co. Ltd. has appointed Ms. Yeung as the new joint company secretary, effective December 30, 2025, following the resignation of Mr. Li Kin Wai from the position of joint company secretary, process agent, and authorised representative.

    Reuters·
    HK
    02291
    -0.37%
    Reuters·
    HK
    02291
    -0.37%

    Calculating The Fair Value Of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (HKG:2291)

    LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (HKG:2291) has an estimated fair value of HK$21.30, with its current share price at HK$21.16, indicating it is trading close to fair value. A two-stage Discounted Cash Flow (DCF) model was used to estimate future cash flows, resulting in a total equity value of CN¥6.8 billion. The analysis suggests the company is fairly valued, with a slight 0.7% discount to its current stock price. However, valuations can be imprecise and should be approached with caution.

    Simplywall·
    HK
    02291
    -0.37%
    Simplywall·
    HK
    02291
    -0.37%

    Haitong International initiates coverage on SCIENTECH with an "Outperform" rating and a target price of 28.94 yuan

    Haitong International initiates coverage on SCIENTECH with an "Outperform" rating and a target price of 28.94 yuan. It is expected that the earnings per share for 2025, 2026, and 2027 will be 0.89 yuan, 1.15 yuan, and 1.45 yuan respectively, with a reference price-to-earnings ratio of 30 times. The company is a leader in congenital heart disease interventional medical devices in China, with traditional business steadily improving and the development of heart valve products as a second growth curve, which has significant profit enhancement potential in the next one to five years

    AASTOCKS·
    HK
    02291
    -0.37%
    AASTOCKS·
    HK
    02291
    -0.37%

    Haitong International: Initiates coverage on SCIENTECH with an "Outperform" rating and a target price of HKD 28.94

    Haitong International initiates coverage on SCIENTECH with an "Outperform" rating and a target price of HKD 28.94. It is expected that the CAGR of the cardiac valve intervention market from 2021 to 2025 will reach 69.8%. The company's revenue for the first half of 2025 is projected to be RMB 330 million, a year-on-year increase of 32.4%; net profit attributable to the parent company is expected to be RMB 182 million, a year-on-year increase of 29.8%. SCIENTECH is a leader in the field of congenital heart disease intervention devices, and its biodegradable products reduce complications, providing significant clinical advantages

    Zhitong·
    HK
    02291
    -0.37%
    Zhitong·
    HK
    02291
    -0.37%

    Lepu Scientech Reports 32.4% Increase in Revenue and 29.8% Rise in Net Profit for H1 2025

    Lepu Scientech Medical Technology Shanghai Co. Ltd. reported a 32.4% increase in revenue for H1 2025, reaching RMB 329.7 million, and a 29.8% rise in net profit to RMB 182.0 million. Despite these gains, the Board will not recommend an interim dividend, consistent with the previous year. The company focuses on developing heart disease interventional medical devices, leveraging over 20 years of industry experience.

    Reuters·
    HK
    02291
    -0.37%
    Reuters·
    HK
    02291
    -0.37%
    © 2025 Longbridge｜Disclaimer